Why did reported profit fall 70% while the underlying business grew? The Novartis Q3 2026 results, released on 27 October 2026, are a useful lesson in the difference between reported and core earnings. Reported net income dropped to $1.20 billion from $3.93 billion, mainly because of a $1.9 billion partial impairment of del-desiran, a drug for myotonic dystrophy type 1 whose Phase III HARBOR trial missed its primary endpoint. Yet core operating income rose 11% and the company raised its full-year core operating income outlook. This article walks through the numbers for readers who follow the pharma sector.
Key takeaways from the Novartis Q3 2026 results for readers of the numbers
- Net sales: $14,522 million, up 4% in US dollars and in constant currencies.
- Reported operating income: $1,843 million, down 59%, with a 12.7% margin against 32.4% a year earlier.
- Core operating income: $6,036 million, up 11%, with a 41.6% margin against 39.3%.
- Free cash flow: $5,111 million, down 18%.
- Net debt: $37.4 billion at 30 September 2026, up from $21.9 billion at the end of 2025.
Reported versus core: the Novartis Q3 2026 results table in words
Reported figures follow IFRS and include every charge. Core figures remove items such as impairments and amortisation of acquired intangibles so that investors can see operating performance. In the third quarter, the reported earnings per share were $0.63 against $2.04, while core earnings per share rose 9% to $2.46. Net income fell 70% in US dollars, and core net income rose 8% to $4.66 billion. Nine-month core operating income was $16.87 billion, down 1%, so the recovery in the third quarter is a notable change. The full release is at novartis.com.
How the impairment shaped the Novartis Q3 2026 results
Novartis said the $1.9 billion charge on the del-desiran in-process R&D asset was the main driver of the fall in operating and net income, alongside higher R&D and other expense. By our own arithmetic, reported operating income plus the charge comes to about $3.7 billion, still below last year’s $4.5 billion. That is our calculation and not a company figure, and it indicates that items beyond the impairment also affected the quarter. The charge is non-cash. It sits in R&D expense, and executives tied it to a later development timeline and the extra clinical work now needed, with a similar chance of success assumed.
The 2026 guidance in the Novartis Q3 2026 results
Novartis now expects 2026 net sales to grow by a low single-digit percentage in constant currencies, unchanged, and core operating income to be in line with last year or to grow by a low single-digit percentage, upgraded from a low single-digit decline. At late-October exchange rates the company expects currency to add about one percentage point to both. On the call, management pointed to second-half net sales growth of mid to high single digits and core operating income growth of high single to low double digits. These are company expectations and can change.
Balance sheet and cash after the Novartis Q3 2026 results
Free cash flow was $5.11 billion for the quarter and $14.0 billion for nine months, down 12%. Net debt rose by about $15.5 billion in nine months. The release attributes this to about $16.7 billion of M&A and other acquisition outflows, a $9.1 billion dividend and $4.8 billion of treasury share outflows, partly offset by free cash flow. Press reports describe del-desiran as a centrepiece of the roughly $12 billion Avidity Biosciences deal, but the company’s release does not itself link the two, so we do not assign a share of the spending to it. Filing: Form 6-K.
The trial result behind the Novartis Q3 2026 results
HARBOR compared del-desiran with placebo in myotonic dystrophy type 1, using video hand opening time as the primary endpoint. The endpoint was not met, though Novartis reports clinical activity in secondary and exploratory analyses. The drug is experimental and not approved. Executives said another Phase III study is still expected, and the full data will be presented at a medical congress. Separately, the Phase III HORIZON trial of pelacarsen missed its primary endpoint; no write-off amount is given in the release, and a $300 million figure mentioned in our brief could not be confirmed, so we omit it.
Sector data from Acumen Research and Consulting
For sector context, Acumen Research and Consulting’s Musculoskeletal Disorders Drugs Market report puts the category at USD 87.8 billion in 2022 and USD 135.3 billion by 2032, a CAGR of 4.5% from 2023 to 2032, with North America above 33% in 2022 and Asia Pacific the fastest-growing region at more than 4.9%. It was last updated in September 2023 and does not size DM1 or del-desiran, so it is context, not a valuation input. See also our pharmaceuticals coverage.
Timeline of the Novartis Q3 2026 results
- 8 September 2026: HARBOR miss reported; press say shares fell as much as 11%.
- 27 October 2026: Q3 results, $1.9 billion impairment and raised core guidance.
- November 2026: management event expected, according to press reports.
General background: why companies publish core figures
Core measures are not defined by accounting standards, so companies choose what to exclude. They help compare performance from year to year but can hide recurring costs. Readers should look at both sets and at the reconciliation table in the filing.
Our analysis of the Novartis Q3 2026 results
In our assessment, the Novartis Q3 2026 results show a healthy underlying business with a pipeline setback attached. The reported profit fall is real but largely non-cash, while the lower free cash flow and higher net debt are cash facts that deserve separate attention. We do not give investment advice or a view on the share price.
What is not disclosed
- Remaining carrying value of del-desiran.
- The cost and timing of another Phase III study.
- Any pelacarsen write-off amount.
Risks and caveats
Core results exclude items the company chooses. Guidance can change. Our arithmetic is illustrative. This article is news reporting and not investment advice.
What to watch next
- Full HARBOR and HORIZON data.
- Fourth-quarter results and any guidance change.
- Regulatory feedback on del-desiran.
FAQ
Why did Novartis profit fall but guidance rise?
Reported profit includes the $1.9 billion impairment, while guidance covers core operating income, which excludes it.
Is the impairment a cash outflow?
No. It is a non-cash accounting charge.
Did sales grow?
Yes, by 4% to $14.52 billion in the quarter.
How we reported this: we relied on Novartis’s release and filing and the Acumen Research and Consulting report cited above and attributed press reports. Our calculations are labelled. Last updated 28 October 2026. This is news reporting and not advice.
